Zaditor

Quick links to important sections

Zaditor

Selected form

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Zaditor

Quick Facts

Property Description
Active Ingredient Ketotifen Fumarate
Form Ophthalmic Solution (Eye Drops)
Pharmacological Class Dual-Acting Antiallergic Agent
Common Use Relief of symptoms from Ocular Allergy
Origin Synthetic Organic Compound

What is the Composition and Form of Zaditor? (Identity and Origin)

Zaditor is a topical medication formulated as an ophthalmic solution, intended for direct application to the surface of the eye. The active constituent is Ketotifen Fumarate, which is a synthetic organic compound derived from the benzocycloheptathiophene chemical class. The preparation is a single-active ingredient product, with Ketotifen present as the fumarate salt, dissolved in an aqueous solution base. This formulation ensures efficient localized delivery, maintaining high concentrations at the site of symptoms while minimizing systemic absorption.

Zaditor's Pharmacological Class and Dual Action

The medicine is a dual-acting antiallergic agent because it functions simultaneously as a second-generation H1-antihistamine and a mast cell stabilizer. As an antihistamine, it works by blocking the H1 histamine receptors that are responsible for the immediate symptoms of an allergy. The complementary action as a mast cell stabilizer is a distinctive feature, preventing specific immune cells from prematurely releasing the full cascade of inflammatory substances. This combination addresses both the instantaneous chemical signaling and the underlying cellular process of allergic inflammation.

General Purpose and Therapeutic Application

The general purpose of this topical ophthalmic agent is to provide sustained relief from the primary physical symptoms associated with ocular allergy, such as those triggered by pollen or pet dander. Its dual mechanism is designed to control the intense itching, redness, and excessive watering that arise from exposure to environmental allergens. The combined therapeutic action is fundamentally aimed at reducing persistent irritation and maintaining ocular comfort.

Regulatory References

  1. Ketotifen Ophthalmic: MedlinePlus Drug Information

What side effects are possible with Zaditor?

Official Adverse Reactions and Safety Classifications

Adverse reactions associated with ketotifen fumarate ophthalmic solution are documented in official regulatory sources and are classified by frequency and the body system affected. In controlled clinical trials, reported side effects were generally mild.

Classification Examples (Organ Systems)
Common (ge 1% to le 10%) Eye disorders: Conjunctival injection, eye irritation, eye pain. Nervous System/Respiratory: Headache, rhinitis.
Uncommon (ge 0.1% to le 1%) Eye disorders: Vision blurred (during instillation), dry mouth, eyelid disorder. General/Skin: Somnolence, rash, eczema.
Frequency Not Known (Post-Marketing) Systemic allergic reactions, including facial edema, and localized hypersensitivity reactions like eye swelling or eyelid edema.

Serious side effects may be reported, and the product is contraindicated in individuals with a known hypersensitivity to any of its components. Safety statements are provided for specific populations; safety and effectiveness have not been established in children below the age of 3 years.

General Safety Constraints

The label notes that the preservative in the drops may be absorbed by soft contact lenses. Therefore, contact lenses must be removed before application. Additionally, due to the potential for blurred vision or somnolence, patients experiencing these effects are advised not to drive or operate machinery. The official safety information structures the understanding of risks by defining the high frequency of minor local effects and delineating clear restrictions on use based on pre-existing conditions and age.

Overdose and Emergency Response

Overdose and when to seek help

The primary overdose pathway for Ketotifen Fumarate Ophthalmic Solution is accidental oral ingestion of the eye drops. Regulatory guidance mandates that if the medicine is swallowed, you must contact a Poison Control Center right away or seek immediate medical attention. This action is required even though the dose in a single 5 mL bottle (approximately 1.725 mg of the active substance) is significantly below the 20 mg dose officially documented to show no serious signs or symptoms upon ingestion.

Systemic overexposure to higher quantities, however, may lead to serious, officially documented clinical manifestations. These severe outcomes primarily affect the Central Nervous System, presenting as profound sedation, confusion, convulsions, and potentially reversible coma. Cardiovascular instability, including tachycardia (fast heart rate) and hypotension (low blood pressure), is also documented. Notably, hyperexcitability may be more evident in the pediatric population.

Management is strictly symptomatic and supportive treatment, as no specific antidote is known. Depending on the clinical assessment, supportive measures may include procedures such as gastric lavage or the administration of activated charcoal.

Therapeutic Uses of Zaditor

What Zaditor Treats: Main Uses and Benefits

This medication is generally used to provide supportive symptomatic relief for a key symptom of eye allergies: intense ocular itching (pruritus). It is applied across therapeutic domains where additional symptomatic support is needed and is considered relevant in conditions characterized by periods of heightened symptoms, specifically allergic conjunctivitis. This includes helping manage symptom clusters that may become intense, such as eye redness, excessive tearing, and general eye irritation.

The drops are commonly used during phases when symptoms become more noticeable due to predictable environmental triggers like pollen, grass, dander, or dust. This offers symptomatic relief that helps patients cope with difficult episodes that interfere with routine activities. The drops are also indicated for the temporary prevention of ocular itching when exposure to a known allergen is anticipated. This provides short-term symptomatic assistance to adults and children (three years of age and older), assisting with supporting day-to-day comfort when symptoms are anticipated.

Therapeutic Summary: Allergic Ocular Itching

Use Case Benefit Focus Patient Group
Allergic Conjunctivitis Helps improve day-to-day comfort Adults and children (3 years and older)
Seasonal Allergies Contributes to improved comfort during periods of heightened symptoms Patients with episodic manifestations

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Population Eligibility for Zaditor

Official regulatory information defines eligibility for Zaditor (ketotifen fumarate ophthalmic solution) based on age and the absence of known hypersensitivity.

Contraindications

Classification Restricted Group
Absolute Contraindication Individuals with a known hypersensitivity or allergy to ketotifen or to any excipients in the product formulation.

Age-Related Eligibility

Status Population
Allowed Adults and Children 3 years of age and older.
Not Established Children younger than 3 years of age. Safety and effectiveness have not been established in this pediatric group.

Special Considerations and Restrictions

While systemic exposure is minimal, regulatory documents advise caution for specific groups and conditions:

  • Pregnancy: Use should be with caution and is generally reserved for cases where the potential benefit justifies the potential risk, as human data are limited.
  • Lactation (Breastfeeding): Caution is advised. It is not known if the drug is excreted in human milk following topical ocular use.
  • Soft Contact Lenses: The product contains benzalkonium chloride. Patients must remove soft contact lenses before application and wait at least ten minutes before reinserting them. The drops must not be used to treat irritation caused by contact lenses.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile for ketotifen fumarate ophthalmic solution is limited, reflecting its topical application and minimal resulting systemic absorption. Regulatory documents focus primarily on administration requirements for co-administered eye preparations and cautions based on the drug's known systemic pharmacology.


Documented Interaction Categories

Interaction Type Official Regulatory Statement
Timing-Based Requirement A mandatory interval of at least 5 minutes must separate the administration of this eye drop and any other topical ophthalmic medication.
Pharmacodynamic Potentiation The use of substances that affect the central nervous system (CNS), such as oral antihistamines and CNS depressants, may have additive effects.
Drug–Substance Caution The official labeling includes a caution regarding potential additive effects when used with alcohol, as the oral form of ketotifen is known to potentiate its effects.

No medicinal products are explicitly listed as formally contraindicated combinations due to interaction risk in the official regulatory prescribing information for the eye drop formulation. Furthermore, no specific metabolic or transporter-mediated interactions (e.g., CYP enzymes) are documented in the product's official interaction section, aligning with the product’s local, non-systemic use. The documented cautions are derived from the necessity to avoid local wash-out and the established properties of the drug's systemically administered form.

Mechanism of Action

Zaditor, which contains the molecule ketotifen fumarate, functions as a dual-acting agent to modulate inflammatory responses in ocular tissue. Its immediate pharmacological mechanism involves competitive antagonism at the histamine H1 receptor. Ketotifen binds to the H1 receptor on target cells, thereby inhibiting the binding of endogenous histamine and disrupting the initial signaling cascade.

This immediate action is complemented by its role as a mast cell stabilizer. Ketotifen regulates the influx of calcium ions into mast cells, an essential step required for the degranulation process. By restricting calcium availability, the molecule limits the secretion of pre-formed and newly synthesized pro-inflammatory mediators, including histamine and leukotrienes, from activated mast cells.

The combined effects of H1 receptor blockade and cellular stabilization modulate the overall allergic pathway. The antagonism disrupts the rapid H1-mediated signaling that causes vasodilation and increased vascular permeability, while the stabilization prevents the later-phase inflammatory cascade dependent on sustained mediator release. These actions restrict local cellular and vascular changes in the conjunctiva triggered by allergen exposure.

Dosage and Administration Information

How to Use Zaditor: Administration Guidelines

Administration Scope

Instruction Detail
Route of administration Topical Ophthalmic Use Only. The product is explicitly not for injection or oral use.
Dosing schedule The standard regimen is one drop administered into the affected eye(s).
Frequency pattern Twice daily (BID), maintaining an interval of approximately 8 to 12 hours between doses. Administration must not exceed twice per day.
Age-group rules Approved for use in adults and children 3 years of age and older.

Procedural Administration Rules

Specific procedural constraints must be followed to ensure proper use, as detailed in the product labeling.

  • Contact Lens Handling: Soft contact lenses must be removed prior to application. A waiting period of at least 10 minutes is required before reinserting soft contact lenses after the dose has been applied.
  • Co-Administration: If the solution is used concurrently with any other ophthalmic product, a minimum interval of 5 minutes must be observed between the administration of each product.
  • Contamination: The dropper tip must not be touched to the eye, fingers, or any other surface to prevent contamination of the solution.
  • Duration: The usage is intended for temporary prevention and relief.

Connection to the Overall Use Protocol

The use protocol establishes a defined, two-times-daily dosing schedule for patients aged 3 and older, strictly limited to the topical ophthalmic route. This protocol integrates specific timing and handling constraints—including the mandatory 8-to-12-hour separation and the rules for contact lens reinsertion—which govern the standardized application of the solution for its period of temporary use.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Zaditor

Evidence for Ocular Itching Associated with Allergic Conjunctivitis

Research exploring the compound Ketotifen Fumarate has centered primarily on short-term studies, many of which are Randomized Controlled Trials (RCTs). These RCTs often involve a controlled setting called the Conjunctival Allergen Challenge (CAC) model, where subjects with known allergies are exposed to an allergen to study symptom patterns. These studies examined patient-reported experiences of ocular itching (pruritus), which is considered the main symptom in allergic conjunctivitis. Researchers monitored how the symptom intensity changed over defined time intervals.

Studies report how symptoms evolved in the observed populations following administration. For instance, in the controlled CAC setting, data show patterns related to the time of the first observed measurement difference and the duration over which the difference was measured. Reported outcomes described that the difference in ocular itching scores between the treatment group and the placebo group was measurable in the short-term challenge models. The evidence informs understanding of short-term symptom patterns related to this primary outcome.

Evidence for Other Physical Signs of Allergic Conjunctivitis

Studies also explored other signs of allergy, such as eye redness (hyperemia) and excessive tearing (lacrimation). These were often tracked as secondary outcomes in the same short-term RCTs. Outcomes describing episodic or acute changes were evaluated in these studies using investigator-rated scales to monitor the severity of the physical signs. Findings were sometimes described with high variability (heterogeneity) across different research settings, especially when data from multiple trials were pooled in systematic reviews.

Long-Term Studies and Uncertainties in the Evidence

Most core regulatory evidence focuses on trials lasting up to two to four weeks. Therefore, the available research exploring short-term symptom changes primarily gives insight into immediate or intermediate responses to episodic symptom patterns. The follow-up durations were limited, meaning there is limited information for long-term outcomes or the durability of the response over an entire allergy season. Data for certain groups, such as children younger than 3 years, remain insufficient. Comparative evidence is sometimes lacking, and the reliance on the artificial CAC model means results apply only to those specific study conditions.

Frequently Asked Questions (FAQ)

Common questions about Zaditor (FAQ)

Q: How quickly does Zaditor start working after I use it?

A: Studies and official information indicate that the anti-itch action of Zaditor occurs rapidly. The relief of ocular itching has been reported to be measurable within minutes after administering the eye drops.

Q: Can Zaditor be used for eye redness that isn't from allergies?

A: According to the official product labeling, this medication is specifically indicated for the temporary relief of itchy eyes due to allergic conjunctivitis, which is caused by common allergens like pollen, dander, and grass. The label does not support its use for eye redness or irritation that is not caused by an allergic reaction.

Q: Can Zaditor cause eye dryness if used frequently?

A: Yes, dry eye has been reported as an adverse reaction in clinical data, though it occurs uncommonly. If dryness or any other side effect becomes persistent or concerning, consulting a healthcare professional is appropriate.

Q: Does Zaditor make you drowsy or affect alertness?

A: Somnolence, or drowsiness, is listed as an uncommon side effect of the medication. Official safety information advises that if blurred vision or somnolence is experienced, driving or operating machinery should be avoided.

Q: What happens if I use Zaditor more than twice a day?

A: Official product information states that the administration frequency must not exceed twice per day. While no serious signs or symptoms have been reported from a large overdose in regulatory documents, exceeding the maximum recommended dose is not advised.

Q: Is Zaditor safe to use during pregnancy or while breastfeeding? (Informational)

A: Regulatory documents advise caution during pregnancy, suggesting use only if the potential benefit justifies the potential risk, as human data are limited. It is also not known if the drug is excreted into human milk following topical ocular use, and caution is advised while breastfeeding.

Q: Why do some people use Zaditor even when they don't have severe eye allergies?

A: The medication is indicated for the temporary relief and prevention of symptoms of seasonal allergic conjunctivitis. Its dual mechanism is designed to control allergy symptoms that arise from exposure to common allergens.

Q: Can Zaditor be used year-round or only during allergy season?

A: The official protocol states the product is intended for temporary prevention and relief of symptoms. While its safety was evaluated in studies lasting up to six weeks, the core evidence focuses on short-term use. For use beyond the typical short-term duration, guidance from a healthcare professional may be needed.

Q: How long is Zaditor good for once the bottle is opened?

A: To maintain the stability and sterility of the product, some official regulatory instructions require that any remaining solution in the multi-dose container must be discarded four weeks after the bottle is first opened.

Q: Are there any studies or research that show how effective Zaditor is for chronic allergies?

A: Most core regulatory evidence focuses on trials lasting up to two to four weeks. As a result, there is limited information available regarding the long-term outcomes or the durability of the response over an entire allergy season or for chronic use.

Q: Does Zaditor help with puffiness or swelling around the eyes?

A: The product works to restrict local cellular and vascular changes caused by the allergic response. While the primary indications are for itching and redness, swelling of the eye or eyelid (edema) has been reported, though rarely, as a sign of hypersensitivity.

Q: Does Zaditor work for all types of eye allergies?

A: The official product labeling indicates the medication is for temporary relief of itchy eyes due to specific outdoor and indoor allergens, which include pollen, ragweed, grass, animal hair, and dander.

Q: Is Zaditor safe for people with glaucoma or high eye pressure?

A: Official product labeling does not include a specific contraindication or precaution against the use of ketotifen ophthalmic solution in patients with pre-existing glaucoma or ocular hypertension.

Q: Can seniors or older adults use Zaditor without any special concerns?

A: The product is approved for use in adults, and clinical studies have not identified a difference in safety or effectiveness between older and younger adult patients. Dosage adjustment is not typically required based on age alone.

Q: What are the signs that Zaditor is not working for my allergy symptoms?

A: Regulatory patient information states that a consultation with a healthcare professional is appropriate if eye itching worsens or lasts longer than 72 hours.

Q: What happens if I accidentally miss a dose of Zaditor?

A: Information regarding the management of a missed dose is provided in the product's official instructions for use.

Q: Why are the drops clear, and what is the pH level of the solution?

A: The solution is described in regulatory documents as a clear, colorless to faintly yellow liquid. The formulation uses an aqueous base and various excipients to maintain a stable and comfortable pH level for direct application to the eye surface.

Q: Can Zaditor be used to prevent allergy symptoms before exposure?

A: Yes, the medication is officially indicated for the temporary prevention and relief of symptoms associated with allergic conjunctivitis.

Q: What kind of research has been done on the long-term safety of Zaditor?

A: Official preclinical data reveal no special hazard relevant to human use based on conventional studies that examine safety pharmacology, repeated dose toxicity, genotoxicity, and carcinogenic potential.

Q: Does Zaditor have any effect on light sensitivity?

A: Yes, eye sensitivity to light, known as photophobia, is listed in regulatory data as an uncommon adverse reaction associated with the use of this medication.

Q: Are there different strengths of Zaditor drops available?

A: The product is generally available as one standardized strength: a 0.025% ketotifen ophthalmic solution.

How should Zaditor be stored and disposed of?

Zaditor (ketotifen fumarate ophthalmic solution) must be stored and handled according to specific conditions defined in regulatory labeling to maintain product stability and sterility.

Storage Conditions

Requirement Official Statement
Temperature Store between 4 C and 25 C (39 F and 77 F); do not freeze.
Protection Store away from direct light.

Container and Stability

To prevent contamination, the bottle must be kept tightly closed, and the cap must be replaced immediately after use without touching the dropper tip to any surface. The contents should be discarded after the labeled expiration date. For multi-dose containers, some official instructions require discarding the remaining solution within four weeks after first opening.

Disposal and Safety

As mandated by safety labeling, the product must be kept out of the reach of children. Disposal of any unused or expired medicine must be done according to local regulations; it must not be disposed of via household waste or wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Zaditor found in:

A-Z Index: